Abstract:Introduction Emerging evidence has suggested that inherited factors are also involved in lung cancer development. However, most studies focused on well-elucidated cancer predisposition genes, the majority of which are tumor suppressor genes. The profile of germline mutations in oncogenic driver genes remains unrevealed, which might also provide potential clinical implications for lung cancer management. Methods Sequencing data from 36,813 unselected lung cancer patients who underwent somatic mutation profiling were retrospectively reviewed. All recruited patients had matched white blood cell samples sequenced in parallel using a capture-based panel including eight key lung cancer driver genes ( epidermal growth factor receptor ( EGFR), anaplastic lymphoma kinase (ALK), MET proto-oncogene, receptor tyrosine kinase (MET), Kirsten rat sarcoma viral oncogene homolog (KRAS) , Erb-B2 receptor tyrosine kinase 2(ERBB2), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), ret proto-oncogene (RET) , and B-Raf proto-oncogene, serine/threonine kinase ( BRAF) ). Likely pathogenic/pathogenic (LP/P) variants were called according to the classification criteria of the American College of Medical Genetics and Genomics. Variants of uncertain significance (VUS) located in the kinase domains of driver genes and occurring recurrently (n ≥3) were also included for further analyses. Results Seven different LP/P variants in EGFR , MET , or RET were identified in 0.03% of lung cancer patients (n = 14) and 25 different VUS in the kinase domains of seven driver genes (except KRAS ) were found with a prevalence of 0.3% (n = 117).Collectively, germline mutations were most frequently seen in ROS1 (n = 31, 0.084%), followed by MET (n = 23, 0.062%), EGFR (n = 22, 0.06%), ALK (n = 22, 0.06%) and RET (n = 17, 0.046%). LP/P variants and VUS fell the most commonly in EGFR (n = 10, 72%) and ROS1 (n = 31, 26%), respectively. Of the 10 patients with EGFR LP/P germline mutation, 70% also acquired somatic EGFR driver mutation exon21 p.L858R or exon19 deletion at baseline; while the three patients with pathogenic germline RET mutation displayed distinct baseline somatic profiles of rare EGFR mutation or KRAS exon2 p.G12C. We discovered 11 germline mutations that also occurred somatically, including four LP/P variants and seven VUS. Conclusion We present the first study to systemically characterize the germline mutation in oncogenic driver genes in a large cohort of unselected patients with lung cancers.

Genomic Profiling of Driver Gene Mutations in Chinese Patients with Non-Small Cell Lung Cancer

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Genomic Characteristics of Driver Genes in Chinese Patients with Non‐small Cell Lung Cancer

Characterization of Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients Using a Novel Targeted Sequencing Panel

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

Identification Of Enriched Driver Gene Alterations In Subgroups Of Non-Small Cell Lung Cancer Patients Based On Histology And Smoking Status

Driver Gene Alterations Profiling of Chinese Non‐small Cell Lung Cancer and the Effects of Co‐occurring Alterations on Immunotherapy

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

A Genome-Wide Comprehensive Analysis of Alterations in Driver Genes in Non-Small-cell Lung Cancer

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Exome Sequencing Identifies Somatic Mutations in Novel Driver Genes in Non-Small Cell Lung Cancer.

Clinical Features and Therapeutic Options in Non‐small Cell Lung Cancer Patients with Concomitant Mutations of EGFR, ALK, ROS1, KRAS or BRAF

Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.

Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy

Expression Profiling of Driver Genes in Female Never-smokers with Non-adenocarcinoma Non–small-cell Lung Cancer in China

Concurrent Oncogene Mutation Profile in Chinese Patients with Stage Ib Lung Adenocarcinoma.

Advances of Immunotherapy for Non-small Cell Lung Cancer with Driver Gene Mutations

Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients

Epidemiological Study of HER-2 Mutations among EGFR Wild-Type Lung Adenocarcinoma Patients in China

Association Between Certain Non–small Cell Lung Cancer Driver Mutations and Predictive Markers for Chemotherapy or Programmed Death‐ligand 1 Inhibition